Can I take myo-inositol if I don't have PCOS but want to balance hormones

Research has not yet evaluated whether myo-inositol can balance hormones in healthy people without PCOS or fertility issues.

Abstract

Myo-inositol—typically given at 2–4 g daily in combination with 200–400 µg folic acid—has been shown to improve ovarian parameters in women with polycystic ovary syndrome. In non-PCOS women undergoing in vitro fertilization, one study reported that myo-inositol reduced gonadotropin requirements (2,084 ± 648 IU versus 2,479 ± 979 IU, $p < 0.05$) and modified luteinizing hormone levels (2.7 ± 1.1 vs. 1.6 ± 0.9, $p < 0.01$) while yielding fewer oocytes (5.9 ± 2.4 vs. 7.6 ± 3.8, $p < 0.01$) and producing no significant differences in pregnancy or implantation rates. No study has evaluated hormone balancing effects in healthy, non-infertile populations outside of the assisted reproduction setting. Mild gastrointestinal side effects have been noted at higher doses, although no substantial safety concerns were reported.

Paper search

Using your research question "Can I take myo-inositol if I don't have PCOS but want to balance hormones", we searched across over 126 million academic papers from the Semantic Scholar corpus. We retrieved the 50 papers most relevant to the query.

Screening

We screened in sources that met these criteria:

- **Population Demographics**: Does the study exclusively include female participants aged 18-45 years without PCOS diagnosis?
- **Intervention Type**: Does the study examine myo-inositol supplementation as a standalone intervention (not combined with other active treatments)?
- **Study Design**: Is the study design either a randomized controlled trial, systematic review, or meta-analysis?
- **Outcome Measures**: Does the study measure hormonal parameters (including any of: FSH, LH, estradiol, or progesterone)?
- **Study Duration**: Was the intervention studied for 4 or more weeks?
- **Medical History**: Are participants free from diagnosed endocrine disorders (except mild thyroid dysfunction)?

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

Data extraction

We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.

- **Study Design**:

  Identify and record the specific type of study design:

- Randomized controlled trial (RCT)
- Systematic review

- Meta-analysis
- Observational study

If an RCT, specifically note:

- Whether it was double-blind
- Whether it was placebo-controlled

Look in the methods section for design details. If design is unclear, mark as "unclear" and note any available information.

- **Participant Characteristics**:

  Extract the following participant details:

- Total number of participants
- Gender (focus on female participants)
- Age range or mean age
- Specific health conditions (e.g., PCOS, menstrual irregularities)
- Inclusion/exclusion criteria

If multiple subgroups exist (e.g., PCOS vs non-PCOS), extract characteristics for each. Use exact numbers and percentages where available. If information is incomplete, note "insufficient data" for that specific characteristic.

- **Myo-Inositol Intervention Details**:

  Record precise details of myo-inositol supplementation:

- Dosage (in grams or milligrams)
- Frequency of administration
- Duration of intervention
- Co-interventions (e.g., folic acid)

If multiple intervention arms exist, extract details for each. Use exact measurements from the methods section. If dosage or duration varies between participants, note the range.

- **Primary Outcomes Measured**:

  List all primary outcomes related to hormone balance and reproductive health:

- Ovulation frequency
- Hormonal markers
- Metabolic indicators
- Reproductive function measures

For each outcome:

- Note the specific measurement method
- Record statistical significance
- Include numerical results (means, percentages)
- Capture confidence intervals if provided

Prioritize outcomes directly addressing hormone balance or reproductive function.

- **Safety and Side Effects**:

  Extract information about:

- Any reported adverse events
- Changes in metabolic parameters
- Weight changes
- Hormonal side effects

Look in results and discussion sections for safety data. Note the frequency and severity of any side effects. If no side effects are reported, explicitly state "No adverse events reported".

Results

Characteristics of Included Studies

Study	Study Design	Population Type	Primary Outcomes Measured	Intervention Details	Full text retrieved
Gerli et al., 2007	Randomized controlled trial (double-blind, placebo-controlled)	Women with oligomenorrhea and polycystic ovaries (polycystic ovary syndrome, PCOS)	Ovulation frequency, time to first ovulation, hormonal and metabolic markers	4 g myo-inositol + 400 mcg folic acid, 14 weeks	No
Lisi et al., 2012	Randomized controlled trial (open-label, controlled)	Non-PCOS women (<40 years) undergoing in vitro fertilization (IVF)	Gonadotropin use, oocyte yield, pregnancy and implantation rates, hormonal markers	4 g myo-inositol/day (2 g twice daily) + 400 µg folic acid, 3 months pre-stimulation and during stimulation	Yes
Torshin et al., 2018	Unclear (narrative review or commentary)	General female reproductive health (no mention found)	Ovulatory cycles, pregnancy probability, metabolic and fetal outcomes (narrative, no quantitative data)	No mention found	No

Study	Study Design	Population Type	Primary Outcomes Measured	Intervention Details	Full text retrieved
Laganà et al., 2018	Systematic review and meta-analysis of randomized controlled trials	PCOS and non-PCOS women undergoing IVF	Gonadotropin use, length of ovarian stimulation	No mention found (review of 8 randomized controlled trials, 812 participants)	No
Sortino et al., 2017	Systematic review and meta-analysis (mainly PCOS)	Women with PCOS	Ovulation, menstrual regularity, hormonal and metabolic markers	2–4 g myo-inositol daily, with folic acid (200–400 µg), duration 8 weeks–6 months	Yes

Study Design

- Most included studies were either systematic reviews/meta-analyses or randomized controlled trials, with one narrative review or commentary.

Population Type

- Two studies focused on women with polycystic ovary syndrome (PCOS).
- One study included non-PCOS women undergoing in vitro fertilization (IVF).
- One systematic review/meta-analysis included both PCOS and non-PCOS women undergoing IVF.
- One study addressed general female reproductive health; we didn't find mention of a specific population for this study.

Primary Outcomes Measured

- Ovulation or menstrual regularity was measured in two studies.
- IVF-related outcomes (gonadotropin use, oocyte yield, length of stimulation) were measured in two studies.
- Hormonal and/or metabolic markers were measured in three studies.
- Pregnancy or implantation rates were measured in one study.
- We didn't find mention of quantitative outcomes in one study (narrative review).

Intervention Details

- Three studies specified a regimen of myo-inositol (2–4 g daily) plus folic acid (200–400 µg), with durations ranging from 8 weeks to 6 months.
- Two studies (including one systematic review/meta-analysis and one narrative review) did not mention intervention details.

Full Text Retrieval

- For two studies, full text was available for extraction; for three studies, only the abstract was available.

Effects

Hormonal Regulation and Reproductive Outcomes

Outcome Measure	PCOS Results	Non-PCOS Results	Clinical Significance
Ovulation frequency	Increased ovulation frequency (25% vs 15% placebo, p<0.01); improved menstrual regularity, 61.7% ovulation rate	No mention found outside IVF context	Clinically meaningful in PCOS; not studied in healthy/non-PCOS women
Time to first ovulation	Shorter with myo-inositol (24.5 vs 40.5 days, p<0.05)	No mention found	Relevant for PCOS; not generalizable
Gonadotropin use (IVF)	Reduced in PCOS (meta-analysis, p<0.00001)	Reduced in non-PCOS (Lisi: 2,084±648 vs 2,479±979 IU, p<0.05; meta-analysis, p=0.02)	May reduce medication burden in IVF; unclear relevance outside assisted reproductive technology
Oocyte yield (IVF)	No mention found	Lower in myo-inositol group (5.9±2.4 vs 7.6±3.8, p<0.01)	May be undesirable in IVF; unclear outside assisted reproductive technology
Pregnancy/implantation rates (IVF)	No mention found	No significant difference (pregnancy: 29.8% vs 25.5%, p=0.52; implantation: 18.7% vs 13.3%, p=0.08)	In the included studies, we didn't find evidence of improved fertility in non-PCOS women undergoing IVF
Hormonal markers (luteinizing hormone, estradiol, progesterone)	Increased estradiol, normal progesterone, reduced luteinizing hormone/follicle-stimulating hormone/androgens in PCOS	Higher luteinizing hormone post-downregulation (2.7±1.1 vs 1.6±0.9, p<0.01); estradiol not significantly different	Some hormonal modulation in PCOS; unclear clinical impact in non-PCOS

Summary of findings across studies:

- Ovulation frequency and time to first ovulation:Only assessed in PCOS populations; both showed significant improvement with myo-inositol.
- Gonadotropin use (in IVF):Reported in both PCOS and non-PCOS groups; both showed a reduction with myo-inositol.
- Oocyte yield (in IVF):Only reported in non-PCOS; significant reduction in oocyte yield with myo-inositol.
- Pregnancy/implantation rates (in IVF):Only reported in non-PCOS; no significant difference with myo-inositol.
- Hormonal markers:Reported in both groups; hormonal changes observed in both, with statistical significance in non-PCOS.

Patterns identified:

- Four outcomes with effect and statistical significance were reported in PCOS (ovulation frequency, time to first ovulation, gonadotropin use, hormonal markers).
- Three outcomes with effect and statistical significance were reported in non-PCOS (gonadotropin use, oocyte yield, hormonal markers).
- One outcome with no effect in non-PCOS (pregnancy/implantation rates).
- We didn't find mention of ovulation frequency or time to first ovulation in non-PCOS populations in the included studies.
- We didn't find mention of oocyte yield or pregnancy/implantation rates in PCOS populations in the included studies.

Metabolic Parameters

Outcome Measure	PCOS Results	Non-PCOS Results	Clinical Significance
Insulin sensitivity/glucose metabolism	Improved insulin sensitivity, reduced fasting insulin, improved Homeostatic Model Assessment (HOMA); no change in fasting glucose/insulin in one randomized controlled trial	No mention found	Potential benefit in PCOS/metabolic syndrome; not studied in non-PCOS
Lipid profile	Increased high-density lipoprotein (HDL), improved lipid profile	No mention found	May reduce cardiovascular risk in PCOS; not studied in non-PCOS
Weight change	Weight loss in myo-inositol group, weight gain in placebo	No mention found	Potential benefit in PCOS/obesity; not studied in non-PCOS

Summary:

- Results for insulin sensitivity/glucose metabolism, lipid profile, and weight change were found only in PCOS populations.
  - For insulin sensitivity/glucose metabolism, two studies found improvement and one found no change.
  - For lipid profile and weight change, two studies found improvement.
- In the included studies, we didn't find results for these outcomes in non-PCOS populations.
- We didn't find mention of any outcomes that were assessed in both PCOS and non-PCOS populations.

Safety and Therapeutic Considerations

Dosage Requirements

Study	Dosage and Regimen	Population Type	Notes on Dosage
Gerli et al., 2007	4 g/day myo-inositol + 400 mcg folic acid, 14 weeks	PCOS	Standard dose; we didn't find mention of adverse events in the abstract
Lisi et al., 2012	4 g/day myo-inositol (2 g twice daily) + 400 µg folic acid, 3 months pre-IVF and during stimulation	Non-PCOS IVF	Standard dose; we didn't find mention of adverse events in the full text
Torshin et al., 2018	No mention found	General/unclear	No details provided
Laganà et al., 2018	No mention found (review of 8 randomized controlled trials)	PCOS and non-PCOS IVF	Doses likely similar to above; no mention found in the abstract
Sortino et al., 2017	2–4 g/day myo-inositol, with 200–400 µg folic acid, 8 weeks–6 months	PCOS	Standard dose; mild gastrointestinal side effects at higher doses

Dosage and Regimen:

- Two studies used 4 g/day myo-inositol, both with 400 mcg/µg folic acid.
- One study used a range of 2–4 g/day myo-inositol with 200–400 µg folic acid.
- In two studies, we didn't find mention of the myo-inositol dose.
- Folic acid was co-administered in three studies; we didn't find mention of folic acid in two studies.
- Duration was specified in three studies (ranging from 8 weeks to 6 months); we didn't find mention of duration in two studies.

Population Type:

- Two studies were conducted in PCOS populations.
- One study was in a non-PCOS IVF population.
- One study included both PCOS and non-PCOS IVF populations.
- One study had a general or unclear population type.

Notes on Dosage and Safety:

- Two studies reported use of a standard dose with no mention of adverse events.
- One study reported standard dose with mild gastrointestinal side effects at higher doses.
- For two studies, we didn't find details on adverse events or safety.

Adverse Effects

Study	Adverse Events Reported	Severity/Frequency
Gerli et al., 2007	We didn't find mention of adverse events in the abstract	N/A

Study	Adverse Events Reported	Severity/Frequency
Lisi et al., 2012	We didn't find mention of adverse events in the full text (except mild gastrointestinal at very high doses, not used in study)	N/A
Torshin et al., 2018	We didn't find mention of adverse events in the abstract	N/A
Laganà et al., 2018	We didn't find mention of adverse events in the abstract	N/A
Sortino et al., 2017	Mild gastrointestinal (diarrhea, flatulence, nausea), mild insomnia at high doses; no substantial side effects	Mild, infrequent

Summary of adverse effects:

- Four studies did not mention any adverse events in the available full text or abstract.
- One study reported mild gastrointestinal symptoms (diarrhea, flatulence, nausea) and mild insomnia, all occurring at high doses; these events were described as mild and infrequent, and no substantial side effects were noted.
- Across the included studies, only mild adverse events were reported, and no moderate or severe events were mentioned.

Population-Specific Responses

Study	Population-Specific Findings	Generalizability
Gerli et al., 2007	Benefits limited in morbidly obese (body mass index >37); inverse relationship between body mass index and efficacy	May not generalize to obese or non-PCOS populations
Lisi et al., 2012	Only non-PCOS IVF patients; reduced oocyte yield, no effect on pregnancy rates	Limited to IVF context; not generalizable to healthy women
Torshin et al., 2018	Narrative claims of benefit in various reproductive/metabolic conditions	No primary data; not generalizable
Laganà et al., 2018	Effects on gonadotropin use in both PCOS and non-PCOS; stimulation length reduced only in PCOS	Only IVF populations; not generalizable to non-infertile women
Sortino et al., 2017	Benefits in PCOS; combination with D-chiro-inositol may be superior	We didn't find mention of data for non-PCOS populations in this study

Summary of population-specific findings:

- Two studies included PCOS populations.
- Two studies included non-PCOS IVF populations.
- One study focused on morbidly obese women.
- One study provided only narrative claims without primary data.

Generalizability:

- All five studies indicated limited generalizability beyond the studied populations.
- Three studies were limited to IVF or infertile populations; we didn't find evidence of generalizability to healthy or non-infertile women.
- Two studies were not generalizable to non-PCOS populations.
- One study did not provide primary data and was not generalizable.
- We didn't find any studies that demonstrated generalizability to the general population or to healthy women.

References

A. Laganà, A. Vitagliano, M. Noventa, G. Ambrosini, and R. D'Anna. "Myo-Inositol Supplementation Reduces the Amount of Gonadotropins and Length of Ovarian Stimulation in Women Undergoing IVF: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." *Archives of Gynecology and Obstetrics*, 2018.

F. Lisi, P. Carfagna, M. Oliva, R. Rago, R. Lisi, R. Poverini, C. Manna, et al. "Pretreatment with Myo-Inositol in Non Polycystic Ovary Syndrome Patients Undergoing Multiple Follicular Stimulation for IVF: A Pilot Study." *Reproductive Biology and Endocrinology*, 2012.

M. Sortino, S. Salomone, M. Carruba, and F. Drago. "Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols." *Frontiers in Pharmacology*, 2017.

S. Gerli, E. Papaleo, A. Ferrari, and G. D. Renzo. "Randomized, Double Blind Placebo-Controlled Trial: Effects of Myo-Inositol on Ovarian Function and Metabolic Factors in Women with PCOS." *European Review for Medical and Pharmacological Sciences*, 2007.

Оригинальные статьи, Мио-инозитол микронутриент, для «тонкой, настройки» женской, репродуктивной сферы, I. Torshin, O. Gromova, A. G. Kalacheva, N. Tetruashvili, and V. Demidov. "Myo-Inositol: Micronutrient for "Fine Tuning" of the Female Reproductive Sphere," 2018.